Histone deacetylase inhibitors impair antibacterial defenses of macrophages. by Mombelli, M. et al.
M A J O R A R T I C L E
Histone Deacetylase Inhibitors Impair
Antibacterial Defenses of Macrophages
Matteo Mombelli,1 Je´roˆme Lugrin,1 Ivana Rubino,1 Anne-Laure Chanson,1 Marlyse Giddey,2 Thierry Calandra,1 and
Thierry Roger1
1Infectious Diseases Service, Department of Medicine, Centre Hospitalier Universitaire Vaudois and University of Lausanne; and 2Department of
Fundamental Microbiology, University of Lausanne, Switzerland
Histone deacetylases (HDACs) control gene expression by deacetylating histones and nonhistone proteins.
HDAC inhibitors (HDACi) are powerful anticancer drugs that exert anti-inflammatory and immunomod-
ulatory activities. We recently reported a proof-of-concept study demonstrating that HDACi increase
susceptibility to bacterial infections in vivo. Yet, still little is known about the effects of HDACi on
antimicrobial innate immune defenses. Here we show that HDACi belonging to different chemical classes
inhibit at multiple levels the response of macrophages to bacterial infection. HDACi reduce the
phagocytosis and the killing of Escherichia coli and Staphylococcus aureus by macrophages. In line with
these findings, HDACi decrease the expression of phagocytic receptors and inhibit bacteria-induced
production of reactive oxygen and nitrogen species by macrophages. Consistently, HDACi impair the
expression of nicotinamide adenine dinucleotide phosphate (NADPH) oxidase subunits and inducible nitric
oxide synthase. These data indicate that HDACi have a strong impact on critical antimicrobial defense
mechanisms in macrophages.
The innate immune system plays a crucial role in host
defenses against invasive microorganisms. Professional
phagocytes are key sentinel cells of the innate immune
system. Pathogen recognition relies on the capacity of
phagocytes to sense microbial molecular motifs
(eg, lipopolysaccharide, peptidoglycan, lipopeptides,
mannans, glucans, flagellin, and nucleic acids) via pattern-
recognition receptors comprising Toll-like receptors
(TLRs), nucleotide-binding oligomerization domainlike
receptors (NLRs), retinoic acid–inducible gene I (RIG-I)–
like receptors (RLRs), C-type lectin receptors (CLRs), and
scavenger receptors [1]. The engagement of phagocytic
receptors, either through a direct interaction with
microbial motifs or through the recognition of opsonized
infectious agents, stimulates the engulfment and the de-
livery of the pathogen to the phagosome. Phagosome
maturation by fission and fusion with endosomes and
lysosomes generates the phagolysosome that provides
a powerful microbicidal microenvironment, usually re-
sulting in efficient microbial killing [2, 3]. The release of
proinflammatory cytokines during an infection stimulates
the production of powerful phagocyte activating mole-
cules like interferon c (IFNc).
Reversible acetylation of the e amino groups of lysine
residues from histones and nonhistone proteins (such as
a-tubulin, steroid receptors, HSP90, and regulators of
nuclear import and transcription) is controlled by
histone acetyltransferases and histone deacetylases
(HDACs). Generally, acetylated histones are associated
with active gene transcription, whereas deacetylated
histones are associated with transcription repression
[4–6]. The 18 mammal HDACs have been classified into
class I (HDAC1–3 and 8), class IIa (HDAC4, 5, 7 and 9),
class IIb (HDAC6 and 10), class III (SIRT1–7), and class
IV (HDAC11) HDACs [4, 7]. Small-molecule inhibitors
of class I, II, and IV HDACs were originally identified
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for their potential to induce cellular differentiation, growth ar-
rest, and apoptosis of transformed cells. HDACi targeting class I
and II HDACs have been reported to counteract cancer de-
velopment by reducing tumor angiogenesis, metastasis, and
invasion and antitumor immunity [4–6].
Besides their anticancer properties, HDACi exert immuno-
modulatory activities that have been exploited for the treatment
of inflammatory and autoimmune disease [8]. Recently, we re-
ported that HDACi interfere with the response of innate im-
mune cells stimulated with TLR agonists and increase the
mortality of mice to microbial sepsis [9]. Yet, whether HDACi
impair the phagocytosis and the killing of bacteria by phagocytes
remains unknown. To more deeply characterize the influence of
HDACi on innate immune responses, we investigated whether
HDACi have an impact on key antibacterial defense mechanisms
of macrophages. We report that HDACi reduce the expression of
phagocytic and opsonophagocytic receptors and inhibit the
phagocytosis of Escherichia coli and Staphylococcus aureus, 2 of
the most common infectious agents, by macrophages. Moreover,
HDACi impair the generation of reactive oxygen and nitrogen
species by macrophages infected with bacteria, resulting in
a marked reduction of bacterial killing.
MATERIALS AND METHODS
Cells and Reagents
Animal procedures were approved by the Office Ve´te´rinaire du
Canton de Vaud (authorizations n 876.6) and performed ac-
cording to institution guidelines for animal experiments. We
purchased 8- to 10-week-old female BALB/c mice from Charles
River Laboratories . We obtained mouse bone marrow–derived
macrophages (BMDMs) and thioglycolate-elicited macrophages
as previously described [10, 11]. RAW 264.7 macrophages were
cultured in Roswell Park Memorial Institute (RPMI) 1640 me-
dium containing 2 mmol/L glutamine and 10% fetal calf serum
(FCS) [12]. E. coli O18:K1:H7 (E. coli) and S. aureus AW7
(S. aureus) are clinical isolates obtained from septic patients
hospitalized at the Centre Hospitalier Universitaire Vaudois. We
purchased trichostatin A (TSA) and valproic acid (VPA) from
Sigma-Aldrich, Salmonella minnesota Ultra Pure lipopolysac-
charide (LPS) from List Biologicals Laboratories , and IFNc from
R&D Systems. The concentrations of TSA (dissolved in ethanol)
and VPA (dissolved in phosphate-buffered saline [PBS]) used in
this study were selected based on previous publications [13–18]
and did not affect the viability (Trypan blue staining and
3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide
[MTT] Cell Proliferation and Viability Assay) of BMDMs
($ 85% cell recovery after 18 hours of culture with 20–40 nmol/
L TSA and 1–2 mmol/L VPA with or without bacteria; n 5 6–9
determinations; P . .5 for all conditions). Ethanol and PBS ve-
hicle controls were performed in each experiment. For simplicity
only 1 set of data is presented in each (Figures 2, 4, 5, and 6).
Assay for Bacterial Uptake and Bacterial Killing
E. coli and S. aureus were grown overnight at 37C in tryptic soy
broth (BD Biosciences), washed in PBS, and adjusted to 107
colony-forming units (CFU)/mL in RPMI medium containing
10% FCS. BMDMs (4 3 105 cells in 24-well cell-culture plates,
Costar) were treated with TSA or VPA for 18 hours. Medium
was changed and cells were incubated for 1 hour with bacteria at
a multiplicity of infection of 20 bacteria per macrophage.
Nonadherent bacteria were removed by washing with PBS. Ex-
tracellular bacteria were killed by a 30-minute exposure to either
100 lg/mL of gentamicin (E. coli) or 10 lg/mL of lysostaphin
(S. aureus). We washed and lysed BMDMs. We plated serial
dilutions of cell lysates on agar plates and enumerated colonies
to calculate the number of phagocytosed bacteria. In parallel
wells, BMDMs were treated as previously except that, after 30
minutes of incubation with antibiotics, cells were washed and
incubated for a further 24 hours in culture medium containing
20 lg/mL gentamicin or 10 lg/mL lysostaphin. Bacteria were
enumerated and results expressed as percent changes in bacterial
counts using the following formula: (count after 24 hours/count
after 1 hour) 3 100. Of note, neither TSA nor VPA at the
concentrations used in these assays were toxic for bacteria.
RNA Analysis by Quantitative Real-Time Polymerase Chain
Reaction
RNA was isolated using the RNeasy kit (Qiagen). Reverse tran-
scription was performed using the ImProm II RT System kit
(Promega). Quantitative real-time polymerase chain reaction
(PCR) was performed with a 7500 Fast Real-Time PCR System
using the Power SYBR Green PCR Master Mix (Applied Bio-
systems) and primer pairs (Supplementary Table 1) as previously
described [19]. We tested samples in triplicate. For each mea-
surement, we processed in parallel a standard made of successive
dilutions of a reference complementary DNA. The relative ex-
pression levels of NADPH oxidase subunits and inducible nitric
oxide synthase (iNOS) were reported to the relative expression of
glyceraldehyde-3-phosphate dehydrogenase (Gapdh) and ex-
pressed in arbitrary units (AU). The expression of phagocytic re-
ceptors and TLRs was calculated with the comparative Ct (DDCt)
method . The expression of the target gene was first normalized to
the endogenous control (Gapdh) and then to that of a calibrator
(ie, data obtained from cells cultured with vehicle set at 1). Im-
portantly, the Ct values of Gapdh were not affected by TSA or VPA
(19.246 0.13, 19.106 0.03, 19.306 0.48, 19.216 0.06, and 19.10
6 0.15 in BMDMs cultured for 18 hours withmedium, 20 nmol/L
TSA, 40 nmol/L TSA, 1 mmol/L VPA, and 2 mmol/L VPA, re-
spectively; n 5 6 determinations; P . .05 for all conditions
compared with cells cultured inmedium). In selected experiments,
results were validated using Hprt as an endogenous control.
Flow Cytometric Analysis
BMDMs cultured for 18 hours with TSA (40 nmol/L) and VPA
(2mmol/L) were incubated 30minutes at 4C in PBS containing
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5% FCS, 5 mM ethylenediaminetetraacetic acid (EDTA), 2.4G2
monoclonal antibody, and monoclonal antibodies specific for
macrophage scavenger receptor 1 (Msr1/CD204), CD11c, CD14,
and major histocompatibility complex II (MHC-II) [20]. Ac-
quisition and analysis were performed using a FACSCalibur (BD
Biosciences) and FlowJo 8.5.3 software (FlowJow).
Analysis of Oxidative Burst Using the Dichlorofluorescein
Diacetate Fluorescence Assay
BMDMs (4 3 105 cells in 24-well cell-culture plates) were
cultured as previously described [21] and incubated for 18 hours
with TSA and VPA. Dichlorofluorescein diacetate (DCFDA)
(20 lmol/L, Sigma-Aldrich) was added to the cultures followed
15 minutes later by bacteria (5 3 108 CFU/mL). After 30 mi-
nutes, cell fluorescence was measured by flow cytometry.
Western Blot Analysis
Cell lysates were electrophoresed through polyacrylamide gels
and transferred onto nitrocellulose membranes as previously
described [12]. Membranes were incubated with antibodies di-
rected against iNOS (BD Biosciences), p47phox (Santa Cruz) and
tubulin (Sigma). After washing, membranes were incubated with
horseradish peroxidase (HRP)–conjugated secondary antibody
(Pierce). Signals were revealed using the ECL Western blotting
analysis system (GE Healthcare).
Nitrite/Nitrate Measurements
BMDMs (105 cells in 96-well cell-culture plates) were pre-
incubated for 1 hour with TSA and VPA and stimulated with
LPS (100 ng/mL), IFNc (100 U/mL), E. coli (108 CFU/mL),
and S. aureus (108 CFU/mL). Cell-culture supernatants were
collected after 24 hours. The concentrations of nitrite/nitrate
were measured using the Griess reagent.
Statistics
Statistical analyses were performed using PRISM (GraphPad
Software). Comparisons between the different groups were
performed by analysis of variance and appropriate post hoc
analyses. P values are 2-sided, and values of , .05 were con-
sidered to indicate statistical significance.
RESULTS
HDACi Inhibit Bacterial Phagocytosis by Macrophages
We recently reported that HDACi impair host defenses to
bacterial infection in vivo [9]. Whether HDACi impact the
phagocytosis and the killing of bacteria is currently unknown.
To fill this gap, we first analyzed the phagocytosis of gram-
negative (E. coli) and gram-positive (S. aureus) bacteria by
BMDMs pretreated with 2 chemically unrelated HDACi: TSA,
a hydroxamate widely used as a prototypical broad-spectrum
HDACi, and VPA, a clinically relevant short fatty acid. The dose
and duration of treatment with TSA and VPA were in the range
of those used in cancer preclinical studies or measured in pa-
tients enrolled in cancer clinical trials (VPA) (see for example
[13–18]). We evaluated phagocytosis after 1 hour of contact
between bacteria and macrophages. As shown in Figure 1,
HDACi dose dependently reduced the number of E. coli (2- to
4-fold; P , .05) and S. aureus (1.5- to 2-fold; P , .05) phago-
cytosed by BMDMs.
HDACi Impair the Expression of Phagocytic Receptors
Macrophages express phagocytic scavenger receptors, including
macrophage scavenger receptor 1 (Msr1/SR-AI/CD204), CD14,
CD36, and C-type lectins such as Dectin-1 (encoded by Clec7a)
that mediate the recognition of microbial ligands expressed at
the surface of pathogens and initiate phagocytosis. Macrophages
also express opsonic phagocytic receptors of the integrin family
(integrinaX/Itgax/CD11c, integrinb2/Itgb2/CD18, and integrina5/
Itga5/CD49e) that facilitate the uptake of microorganisms
coated with opsonins like the mannose-binding lectin, comple-
ment subcomponents, growth arrest specific 6, ficolins, and
pentraxins [2, 22]. TSA and VPA reduced 2- to 10-fold Msr1,
Figure 1. Histone deacetylase inhibitors impair the phagocytosis of
Escherichia coli (A) and Staphylococcus aureus (B ). Mouse bone marrow–
derived macrophages (BMDMs) were incubated for 18 hours with
increasing concentrations of trichostatin A (TSA) and valproic acid (VPA)
before the addition of 107 colony-forming units (CFU) of E. coli or
1.53 107 CFU of S. aureus. The number of bacteria ingested by BMDMs
was determined 1 hour later. Data are presented as mean 6 standard
deviation (SD) of quadruplicate samples from 1 experiment representative
of 2–3 experiments. *, .05 , P , .005; **, P , .005.
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CD14, Dectin-1 and Itgax messenger RNA (mRNA) levels in
BMDMs (Figure 2A). TSA inhibited Itgb2 expression more ef-
ficiently than did VPA (2.4-fold with 40 nMTSA vs 1.4-fold with
2 mM VPA), whereas HDACi did not affect CD36, Itga5, or
Itga6 expression. Flow cytometry analyses confirmed that TSA
and VPA inhibited the expression of Msr1, CD11c and CD14 by
BMDMs (Figure 2B). As a control of nonspecific broad in-
hibitory effects of HDACi, MHC-II expression was not affected
by HDACi. All together, these data suggest that reduced ex-
pression of phagocytic receptors may contribute to impair the
phagocytosis of E. coli and S. aureus in macrophages treated with
HDACi.
HDACi Inhibit Bacterial Killing
TLRs play crucial roles in the sensing of invasive microorganisms
and in transmitting signals involved in the maturation of phag-
osomes [23]. Interestingly, we observed that HDACi strongly
reduced baseline expression of TLR1–7 and TLR9 in BMDMs
(Figure 2C). Pathogen delivery to phagolysosomes usually results
in effective microbial killing [2, 24]. In agreement,, 5% of E. coli
and 25% of S. aureus phagocytosed by BMDMs were recovered
24 hours later in macrophages (P , .001; Figure 3). TSA and
VPA reduced 5-fold and 3-fold E. coli and S. aureus killing, re-
spectively (ie, increasing bacteria recovery to 25% and 75% of the
ingested inoculum; P , .05). Thus, HDACi inhibit both the
phagocytosis (Figure 1) and the killing (Figure 3) of bacteria by
macrophages, in agreement with the observation that HDACi
increased the susceptibility of mice to microbial infection [9].
HDACi Interfere With the Generation of Reactive Oxygen
Species
In response to microbial challenge, macrophages produce highly
toxic reactive oxygen species (ROS) that contribute to pathogen
destruction [25]. The generation of ROS in BMDMs was ana-
lyzed by flow cytometry using the cell permeable nonfluorescent
dye 2#,7#-dichlorofluorescein diacetate (DCFDA) that is trans-
formed on oxidation into the highly fluorescent DCF. E. coli and
S. aureus strongly increased DCF fluorescence in BMDMs,
which was inhibited 2- to 3-fold by TSA or VPA (Figure 4A and
4B). HDACi also inhibited the production of ROS in BMDMs
stimulated with phorbol myristate acetate (.10-fold reduction,
data not shown) indicating that HDACi inhibit the oxidative
burst induced by microbial and nonmicrobial stimuli.
In macrophages, ROS are generated during the respiratory
burst through the action of the phagocytic NADPH oxidase,
an enzymatic complex composed of 2 membrane-associated
subunits (gp91phox/NOX2 and p22phox), 3 cytosolic subunits
(p47phox, p40phox, and p67phox), and the Rac2 regulatory subunit
[26, 27]. Cytokines, particularly IFNc, and microbial products
released during an infection prime and amplify macrophage
respiratory burst through the induction of NADPH oxidase
subunits [21]. Real-time PCR and Western blot analyses re-
vealed that TSA and VPA dose-dependently inhibited baseline
expression of NADPH oxidase subunits and potently inhibited
the upregulation of the catalytic gp91phox and regulatory p47phox
Figure 2. Histone deacetylase inhibitors inhibit the expression of
phagocytic and Toll-like receptors. A, Real-time polymerase chain reaction
(PCR) analysis of Msr1, CD14, CD36, Clec7a, Itgax, Itgb2, Itga5, and Itga6
messenger RNA expression in mouse bone marrow–derived macrophages
(BMDMs) incubated for 8 hours with increasing concentrations of
trichostatin A (TSA) and valproic acid (VPA). Data are presented as
mean6 standard deviation (SD) of triplicate samples from 1 experiment and
are representative of 2 independent experiments. B, Flow cytometry analysis
of Msr1, CD14, CD11c, and major histocompatibility complex II (MHC-II)
expression by BMDMs incubated for 18 hours with medium (gray area), TSA
(dashed line), and VPA (solid line). Results are representative of 2
independent experiments. C, Real-time PCR analysis of Toll-like receptors in
BMDMs incubated for 8 hours with increasing concentrations of TSA and
VPA. Data are presented as mean 6 standard deviation (SD) of triplicate
samples from 1 experiment and are representative of 2 independent
experiments. AU, arbitrary units; *, .05 , P , .005; **, P , .005.
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subunits in LPS1IFNc–stimulated macrophages (Figure 5). All
together, these data provide compelling evidence that HDACi
inhibit ROS production in macrophages.
HDACi Inhibit Nitric Oxide Production and iNos Gene
Expression
Nitric oxide (NO) is produced during the nitrosative burst by
iNOS and represents an important antimicrobial effector
mechanism [25, 27]. TSA and VPA dose-dependently inhibited
the production of NO by BMDMs stimulated with LPS1IFNc
(50%–80% reduction; P , .05), in line with previous work
showing that HDACi inhibit cytokine-induced NO release
[28, 29]. More relevant for microbial infection, TSA and to
a lesser extent VPA inhibited NO production induced by E. coli
and S. aureus (50%–60% reduction using 20 nmol/L and 40
nmol/L TSA and 30%–35% reduction using 2 mmol/L VPA;
P, .05) (Figure 6A). In agreement with these findings, real-time
PCR andWestern blot analyses demonstrated that TSA and VPA
inhibited iNOS mRNA and protein expression in BMDMs
(Figure 6B and 6C). Similar results were obtained using thio-
glycolate-elicited peritoneal and RAW 264.7 macrophages (data
not shown). Taken together, these results suggest that HDACi
impair NO production by BMDMs in response to bacterial
challenge by interfering with iNOS expression.
DISCUSSION
In this study, we report for the first time to our knowledge that
HDACi inhibit the phagocytosis and the killing of bacteria, the
expression of phagocytic receptors, and the generation of oxi-
dative and nitrosative bursts induced by bacteria in macro-
phages. These data extend our previous work demonstrating
that HDACi interfere with cytokine production by macrophages
and impair host defenses to bacterial infection [9].
The inhibition of E. coli and S. aureus phagocytosis by
HDACi was associated with a reduced expression of phago-
cytic receptors, among which is Msr1 (scavenger receptor A1).
Msr1 binds a wide range of microbial ligands and mediates
Figure 3. Histone deacetylase inhibitors impair the killing of
Escherichia coli and Staphylococcus aureus. Mouse bone marrow–
derived macrophages (BMDMs) were cultured for 18 hours with
increasing concentrations of trichostatin A (TSA) and valproic acid
(VPA) before the addition of 107 colony-forming units (CFU) of E. coli (A) or
1.5 3 107 CFU of S. aureus (B ). The number of bacteria recovered from
macrophages after 24 hours was divided by the number of bacteria
recovered after 1 hour and expressed in percentage using the formula
(count after 24 hours/count after 1 hour) 3 100. Data are presented as
mean 6 standard deviation (SD) of quadruplicate samples from 1
experiment representative of 2–3 experiments. *, .05 , P , .005;
**, P , .005.
Figure 4. Histone deacetylase inhibitors interfere with the generation
of reactive oxygen species. Mouse bone marrow–derived macrophages
(BMDMs) were incubated with trichostatin A (TSA; 40 nmol/L) and
valproic acid (VPA; 2 mmol/L) and exposed to Escherichia coli or
Staphylococcus aureus as described in Material and Methods. A, The
generation of reactive oxygen species (ROS) was quantified by flow
cytometry by measuring dichlorofluorescein (DCF) diacetate oxidation into
fluorescent DCF. B, Data are means 6 standard deviation (SD) of 2
independent determinations. P5 .03 and .008 for E. coli and S. aureus vs
control. *, P5 .05; **, .05 , P , .005 vs E. coli– and S. aureus–treated
cells.
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nonopsonic phagocytosis of E. coli and S. aureus [30].
Moreover, Msr12/2 mice are more susceptible than wild-type
mice to S. aureus infection [31]. Thus, HDACi-mediated in-
hibition of Msr1 expression may well help impair bacterial
phagocytosis, although HDACi may target other phagocytic
receptors such as the mannose receptor, MARCO, or CD14.
Of note, HDACi decreased Dectin-1 expression in BMDMs.
Considering that Dectin-1 is a major receptor involved in the
recognition of b-glucan, we speculate that HDACi may affect
the phagocytosis of yeast. In line with this hypothesis, we
observed that VPA increases mortality of mice infected with
Candida albicans [9].
The ax and b2 integrin subunits contribute to the structure of
complement receptor (CR) 3 and CR4 that mediate the recog-
nition of opsonized microorganisms by phagocytes. b2 integrins
play an important role in antimicrobial defenses as suggested by
the observation that patients with leukocyte adhesion deficiency
type I (LADI) syndrome (ie, patients deficient in functional b2
integrin) have defects in phagocytosis and are prone to bacterial
infections [32]. All together, inhibition of the expression of ax
and b2 integrins and scavenger and lectin receptors by HDACi
support the contention that HDACi interfere with bacterial
opsonic and nonopsonic phagocytosis.
HDACi powerfully inhibited the killing of E. coli and S. aureus
bymacrophages. This observation is congruent with the fact that
VPA treatment increased the proportion and the magnitude of
bloodstream infections in mice infected with Klebsiella pneu-
moniae [9]. Reactive oxygen and nitrogen species are among the
most deleterious components produced by phagocytes and
implicated in the destruction of microorganisms [2, 24]. De-
ficiency in members of the NADPH oxidase complex or in
iNOS, which control the generation of superoxide (O2
2) and
nitric oxide (NO) radicals, impair the killing of E. coli and
S. aureus by innate immune cells and compromise mouse
Figure 5. Histone deacetylase inhibitors inhibit nicotinamide adenine
dinucleotide phosphate (NADPH) oxidase subunits expression. A, Real-time
polymerase chain reaction (PCR) analysis of gp91, p22, p47, p67, p40, and
Rac2 messenger RNA expression in mouse bone marrow–derived macro-
phages (BMDMs) cultured for 8 hours with trichostatin A (TSA) and valproic
acid (VPA). Results are expressed as the ratio of the gene of interest to that of
glyceraldehyde-3-phosphate dehydrogenase. Real-time PCR (B ) and
Western blot (C ) analyses of gp91 and p47 expression in BMDMs
cultured for 1 hour with TSA and VPA and then stimulated for 6 hours with
lipopolysaccharide (LPS; 100 ng/mL)1 interferon c (IFNc; 100 U/mL). Data
are presented as means 6 standard deviation (SD) of triplicate samples
from 1 experiment and are representative of 2 independent experiments
(A, B ). Abbreviation: AU, arbitary units.*, P , .005 vs control (A) and
LPS1IFNc (B ).
Figure 6. Histone deacetylase inhibitors impair nitric oxide production and
iNos gene expression. Mouse bone marrow–derived macrophages (BMDMs)
were cultured for 1 hour with trichostatin A (TSA) and valproic acid (VPA)
and then stimulated with lipopolysaccharide1 interferon c (100 ng/mL and
100 U/mL), Escherichia coli (108 colony-forming units [CFU]/mL), and
Staphylococcus aureus (108 CFU/mL) for 24 hours (A) or 8 hours (B–C ).
A, Nitrite/nitrate concentration in cell culture supernatants was measured
using the Griess reagent. Data are presented as mean6 standard deviation
(SD) of triplicate samples from 1 experiment and are representative of
4 independent experiments. Real-time polymerase chain reaction (PCR) (B )
and Western blot (C ) analyses of inducible nitric oxide synthase (iNOS)
expression. Results are expressed as the ratio of iNOS mRNA levels to that
of glyceraldehyde-3-phosphate dehydrogenase. Data are means 6 SD of
triplicate samples from 1 experiment and are representative of 3 independent
experiments. Abbreviation: AU, arbitrary units. *, .05 , P , .005; **,
P , .005.
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survival [33–36]. Moreover, germ-line mutation in 1 of the
components of NADPH oxidase complex results in chronic
granulomatous disease characterized by recurrent bacterial and
fungal infections and reduced life expectancy [25]. Inhibition of
NADPH oxidase subunit and iNOS expression and of reactive
oxygen and nitrogen species generation by HDACi likely rep-
resents an effective mechanism by which these drugs impair the
killing of bacteria.
In agreement with the notion that phagocytosis is coupled
with a proinflammatory cytokine response and with the obser-
vation that HDACi inhibit TLR expression, HDACi strongly
impaired the secretion of cytokines and chemokines (TNF, IL-6,
IL-12p40, and MIP-2a, data not shown) by macrophages in-
fected with E. coli and S. aureus. These data expand on recent
studies showing that HDACi inhibit cytokine production in-
duced by cytokines and purified microbial products in innate
immune cells [14, 15, 28, 37, 38]. Considering that proin-
flammatory mediators released during the course of an infection
coordinate the development of innate and adaptive immunity,
one may expect that HDACi interfere with the generation of
pathogen-specific adaptive immune response.
HDACi have been reported to interfere with signaling path-
ways controlling the expression of genes particularly relevant for
this study. Indeed, HDACi down-regulate the expression of
PU.1 transcription factor [37, 39], which regulates constitutive
expression of HDACi-target genes encoding for integrins,
scavenger receptors, TLR4, CD14, and p40, p47, and p67
NADPH oxidase subunits [20, 40]. Moreover, HDACi have been
reported to interfere with the activation of mitogen-activated
protein kinases, NF-jB, and AP-1, which control inflammatory
and antimicrobial host responses [15, 41]. HDACi also impair
gene expression through chromatin modifications or aceytlation-
dependent recruitment of transcriptional repressors, albeit these
mechanisms are less well characterized. For example, TSA in-
hibits the expression of the proinflammatory cytokine macro-
phage migration inhibitory factor through a local deacetylation
of migration inhibitory factor-promoter–associated histones
impairing the recruitment of the basal transcriptional machinery
[42, 43]. Finally, we have recently shown that TSA inhibits
macrophage response to LPS stimulation by inducing the ex-
pression of Mi-2b and the activity of the Mi-2/NuRD tran-
scriptional repressor complex [9].
HDACi have been used to treat inflammatory diseases in
mouse models [8]. Abundant preclinical and clinical studies
indicate that interfering with critical mediators of innate or
adaptive immunity increases the risk of infections. Thus, one
may question whether HDACi might affect natural host defenses
in patients, as could be anticipated from the powerful immu-
nomodulatory and anti-inflammatory activities of HDACi in
vivo [8] and the increased susceptibility to bacterial and fungal
infections of mice treated with HDACi [9]. Patients treated with
HDACi (suberoylanilide hydroxamic acid, MS-275, valproate,
and ITF2357) in phase I and II clinical trials have developed
episodes of severe infection even in the absence of treatment-
induced neutropenia [44–49], suggesting the need to monitor
the immune status and susceptibility to infection of patients
treated with HDACi, especially immunosuppressed cancer
patients [4–6, 50].
In summary, this study demonstrates that HDACi impair the
capacity of macrophages to ingest and destroy gram-positive
and gram-negative bacteria. The fact that HDACi impede the
expression of phagocytic receptors, the generation of oxygen-
and nitrogen-reactive species, and the release of proin-
flammatory cytokines provide a plausible mechanism whereby
HDACi negatively impact critical antimicrobial functions of
innate immune cells and increase the susceptibility of mice to
bacterial and fungal infection [9].
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